No Data
Stocks that moved the previous day part2 include Qualipus, Veru Inc, and Sakura Internet, etc.
Stock name <Code> 21-day closing price ⇒ day-to-day comparison KADOKAWA <9468> 4170 -218 Sony's consideration for acquisition has led to a sharp rise, with a subsequent increase in recoil. ANYCOLOR <5032> 2160 -52 Particularly with no specific material, awareness of resistance due to factors such as the upper shadow on the 20th. Torii Pharmaceuticals <4551> 4665 -90 Could there be a scenario where profit-taking sell trades accumulate at high levels? Sakura Internet <3778> 4475 -230 NVIDIA is leading the way in extended hours trading with sell trades. Socionext
Emerging markets stock digest: Agile rebounds, BTM hits limit up.
<5247> BTM 1567 +300 limit-up. After the close of trading on the 20th, it announced the establishment of a subsidiary specialized in AI technology in order to accelerate DX for local businesses and municipalities, as well as to enter the AI market, which is being regarded as positive news. By leveraging the talent network developed across japan and the ability to recruit and train local human resources, it aims to form a specialized group of excellent AI engineers to independently develop systems and solutions in the AI domain.
Digest of hot stocks (morning session): Foster Electric, Koisaido HD, Axle M, etc.
Foster Electric <6794>: 1486 yen (-333 yen) significantly dropped. The day before, a briefing on the first half financial results was held, along with the announcement of the medium-term business plan. In the medium-term plan, targets have been set for the final year ending in March 2028, with revenue of 150 billion yen (forecast for March 2025 is 135 billion yen), operating profit of 9 billion yen (the same as 6.5 billion yen), and a target ROE of 8.0%. Furthermore, proposals to enhance shareholder returns include raising the dividend payout ratio to 40% and a DOE minimum of 2%. However, the target figures are considered to have limited surprises.
Symbio Pharmaceuticals etc. continue to rank, presenting research results at the annual meeting of the usa Hematology Society.
Symbio Pharmaceutical <4582> has ranked in (as of 10:32 AM). A significant rebound. It has been announced that results of a joint research with the National Cancer Center of Singapore regarding the possibility of using the injectable Brincidofovir in combination with immune checkpoint inhibitors for non-Hodgkin lymphoma will be presented at the 66th Annual Meeting of the usa Hematology Society to be held from December 7 to 10, which seems to be a key factor. Top changes in volume [November 21.
Volume change rate ranking (9 AM) - Koisaido HD, Def Consulting, etc. are included in the ranking.
In the volume change rate ranking, you can understand the market participants' interest in trends such as targeting by comparing the average volume of the past 5 days with the volume on the day of delivery. Top volume change rate [As of 9:32 on November 21] (Comparison with the average volume of the past 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <4833> Def Consultation 5025 1001 7185.08 288.92% 0.30 37%
Shionogi Pharmaceutical - announces rebound, potential for combination therapy at the annual meeting of the American Society of Hematology.
A rebound. It has been announced that research results regarding the combination therapy of the injectable Brensetimab with immune checkpoint inhibitors for non-Hodgkin lymphoma, conducted in collaboration with the National Cancer Center of Singapore, will be reported at the 66th Annual Meeting of the American Society of Hematology, held in San Diego, California, from December 7 to 10. This has been well received. Non-Hodgkin lymphoma is a disease where lymphocytes become cancerous, which includes B-cell lymphoma and T-cell lymphoma.
No Data
No Data